向铁亡:阿克酸作为萨尔索林醇诱导的帕金森病模型中的神经保护剂
Hongquan Wang1, Shuang Wu2, Qiang Li3
1Department of Geriatrics, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, 100049 Beijing, China.
Frontiers in bioscience (Landmark edition)
|February 28, 2025
概括
萨尔索林醇通过促进铁亡,诱导帕金森病的神经毒性. 植物衍生化合物阿克化物通过抑制这个过程提供神经保护,这表明了新的治疗点.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 萨尔索林醇 (SAL) 是一种内源性神经毒素,与帕金森病 (PD) 发病有关.
- 精确的SAL诱导的神经毒性机制,特别是在多巴胺基神经元中,需要进一步阐明.
研究的目的:
- 为了研究 SAL 诱导的神经毒性背后的分子机制.
- 在PD模型中探索actesoid对SAL诱导的神经毒性的潜在神经保护作用.
主要方法:
- RNA测序和KEGG分析在SAL处理的SH-SY5Y细胞中发现了差异表达的基因.
- 建立了PD动物模型并用actesoid进行处理,同时进行细胞活力测定,脂质过氧化评估,免疫染和电子显微镜.
主要成果:
- 发现SAL通过在SH-SY5Y细胞中调节长链乙基-CoA合成酶家族成员4 (ACSL4) 的上调来丰富与铁亡相关的途径.
- 铁酶抑制剂 (ferrostatin-1,deferoxamine) 逆转了SAL诱导的神经毒性.
- 在体外和体外的PD模型中,acteoside通过抑制ferroptosis和降低ACSL4的调节来减弱SAL诱导的神经毒性.
结论:
- 在PD中,SAL诱导的神经毒性通过诱导ferroptosis,由ACSL4.4调解而发生.
- 乙酸通过抑制铁化,证明了针对PD的新型药理学效应.
- 向SAL诱导的铁亡是一种对帕金森病的潜在治疗策略.
相关概念视频
Parkinson's Disease: Treatment
182
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
182
Parkinson's Disease: Overview
419
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
419


